SHILPA MEDICARE LTD. Q1 FY26 Results

Summary

Shilpa Medicare has shown remarkable progress in FY2024-25 across its core business verticals of APIs, Formulations, and Biosimilars. The API division is breaking new ground in developing high-value molecules, the Formulations division is redefining treatment paradigms with first-to-market innovations, and the Biosimilars division is gaining momentum with strong market performance and global expansion. The company is also expanding its footprint in Rest of World markets and advancing its CDMO business.

Key Highlights

1. 1

   38% Annual Report 2024-25

2. 2

   Significant strides with development of complex APIs in Oncology

3. 3

   R&D pipeline remains future-focussed with ongoing development of GLP-1 blockbusters like Liraglutide and Semaglutide

4. 4

   CEP approvals for Desmopressin and Octreotide

5. 5

   Developed Ready-to-Use Oncology product for US market with Pemetrexed

6. 6

   Approval for Bortezomib in RTU subcutaneous formulation

7. 7

   Approval for first oral fluid formulation, Imatinib, in home market

8. 8

   Adalimumab demonstrating strong market performance and growing share post-launch

9. 9

   Initiation of Phase III clinical trials for second biosimilar product, Aflibercept

10. 10

    Strategic partnership with Orion Corporation for the European commercialization of rHA

11. 11

    Robust R&D and manufacturing capabilities for CDMO business